HSV1716
AXP000073.1 · Oncolytic virus
- Platform
- HSV-1 (strain 17+, RL1/ICP34.5 deleted)
- Originator
- University of Glasgow (MRC Institute of Virology)
- Sponsor
- Virttu Biologics (Sorrento Therapeutics)
Names
| Name | Type | Source |
|---|---|---|
| HSV1716 | preferred name, code | curator, ncit |
| Seprehvir | brand | ncit |
| RL1 mutant HSV-1 1716 | synonym | curator |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Strain
- 17+
- Replication
- conditionally replicating
- Modifications
- both copies of RL1 (ICP34.5) deleted; no transgene
- Route
- intratumoral, intracerebral, intravenous, intrapleural
- Source
- evidence
Cross-references
- NCI Thesaurus
- C84840
- FDA UNII
- 26WEP2905N
Approvals
No regulatory approval recorded.
Clinical trials (3)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT02031965 | Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery | Terminated | Phase 1 | 2013-12 | 2016-05 | 2 | Recurrent Childhood Anaplastic Astrocytoma; Recurrent Childhood Anaplastic Oligoastrocytoma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Giant Cell Glioblastoma; Recurrent Childhood Glioblastoma; Recurrent Childhood Gliomatosis Cerebri; Recurrent Childhood Gliosarcoma |
| NCT01721018 | Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. | Completed | Phase 1/2 | 2012-10 | 2016-11-14 | 12 | Malignant Pleural Mesothelioma |
| NCT00931931 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | Completed | Phase 1 | 2010-03 | 2018-03-19 | 18 | Clival Chordoma; Ewing Sarcoma; Malignant Peripheral Nerve Sheath Tumor; Neuroblastoma; Non-CNS Solid Tumors; Osteosarcoma; Rhabdomyosarcoma; Soft Tissue Sarcoma; Wilms Tumor |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 33160198 | Oncolytic herpesvirus therapy for mesothelioma - A phase I/IIa trial of intrapleural administration of HSV1716. | Lung cancer (Amsterdam, Netherlands) | 2020 | name in title: HSV1716 |
| PMID 31570234 | First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. | Molecular therapy : the journal of the American Society of Gene Therapy | 2019 | name in title: Seprehvir |
| PMID 28495911 | Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2017 | name in title: HSV1716 |
| PMID 18615711 | Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. | Head & neck | 2008 | name in abstract: HSV1716 |
| PMID 16829761 | Assessment of 123I-FIAU imaging of herpes simplex viral gene expression in the treatment of glioma. | Nuclear medicine communications | 2006 | name in abstract: HSV1716 |
| PMID 11229673 | Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. | Lancet (London, England) | 2001 | name in abstract: HSV1716 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41705010 | A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy. | Cureus | 2026 | name in abstract: HSV1716 |
| PMID 41741902 | Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors. | Journal of neuro-oncology | 2026 | name in abstract: HSV1716 |
| PMID 42072616 | Exercise Boosts the Immune System and Enhances Immunotherapy Responses in Pancreatic Cancer and Mesothelioma. | Biomolecules | 2026 | name in abstract: HSV1716 |
| PMID 42609452 | Oncolytic HSV1716 attenuates tumor-killing activity of infected primary NK cells. | Frontiers in immunology | 2026 | name in title: HSV1716 |
| PMID 40685482 | Oncolytic virotherapy and tumor microenvironment modulation. | Clinical and experimental medicine | 2025 | name in abstract: HSV1716 |
| PMID 39239066 | Synergistic effects of herpes oncolytic virus and cyclophosphamide for recurrent malignant glioma: a narrative review. | Annals of medicine and surgery (2012) | 2024 | name in abstract: HSV1716 |
| PMID 36992311 | HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models. | Viruses | 2023 | name in title: HSV1716 |
| PMID 37749907 | Oncolytic virotherapies for pediatric tumors. | Expert opinion on biological therapy | 2023 | name in abstract: HSV1716 |
| PMID 35076148 | Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV-1 Virus. | Small (Weinheim an der Bergstrasse, Germany) | 2022 | name in abstract: HSV1716 |
| PMID 35782876 | Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability. | Frontiers in molecular biosciences | 2022 | name in title: HSV1716 |
| PMID 33298589 | Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. | Molecular cancer therapeutics | 2021 | name in title: HSV1716 |
| PMID 29543735 | High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. | Viruses | 2018 | name in title: HSV1716 |
| PMID 29896663 | Oncolytic Virotherapy by HSV. | Advances in experimental medicine and biology | 2018 | name in abstract: HSV1716 |
| PMID 28147331 | Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation. | Oncotarget | 2017 | name in abstract: HSV1716 |
| PMID 28547002 | Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. | Molecular therapy oncolytics | 2017 | name in abstract: HSV1716 |
| PMID 29034312 | TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma. | Molecular therapy oncolytics | 2017 | name in abstract: HSV1716 |
| PMID 26583803 | Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility. | Gene therapy | 2016 | name in abstract: Seprehvir |
| PMID 26284300 | Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting. | Nature communications | 2015 | name in abstract: Seprehvir |
| PMID 27508184 | Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models. | Journal of hepatocellular carcinoma | 2014 | name in title: HSV1716 |
| PMID 22414636 | In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2012 | name in title: HSV1716 |
| PMID 22595793 | Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy. | Cancer gene therapy | 2012 | name in title: HSV1716 |
| PMID 20205051 | HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases. | Current opinion in drug discovery & development | 2010 | name in abstract: HSV1716 |
| PMID 19528476 | Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy. | Anticancer research | 2009 | name in abstract: HSV1716 |
| PMID 17928799 | GADD34 gene restores virulence in viral vector used in experimental stroke study. | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism | 2008 | name in abstract: HSV1716 |
| PMID 18458533 | Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. | Cancer biology & therapy | 2008 | name in abstract: HSV1716 |
| PMID 18701918 | A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein. | Gene therapy | 2008 | name in title: HSV1716 |
| PMID 17763002 | Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma. | Acta oto-laryngologica | 2007 | name in title: HSV1716 |
| PMID 16574492 | Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein. | Molecular therapy : the journal of the American Society of Gene Therapy | 2006 | name in abstract: HSV1716 |
| PMID 15925544 | HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. | Molecular therapy : the journal of the American Society of Gene Therapy | 2005 | name in abstract: HSV1716 |
| PMID 15960607 | Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. | Human gene therapy | 2005 | name in abstract: HSV1716 |
| PMID 16014957 | Herpes simplex virus type 1 strain HSV1716 grown in baby hamster kidney cells has altered tropism for nonpermissive Chinese hamster ovary cells compared to HSV1716 grown in vero cells. | Journal of virology | 2005 | name in title: HSV1716 |
| PMID 16787326 | Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy. | Medicinal chemistry (Shariqah (United Arab Emirates)) | 2005 | name in title: HSV1716 |
| PMID 15334111 | HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. | Gene therapy | 2004 | name in title: HSV1716 |
| PMID 12898637 | Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours. | The journal of gene medicine | 2003 | name in title: HSV1716 |
| PMID 14682372 | Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. | Journal of neuro-oncology | 2003 | name in abstract: HSV1716 |
| PMID 11960316 | The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. | Gene therapy | 2002 | name in title: HSV1716 |
| PMID 12170384 | HSV1716 persistence in primary human glioma cells in vitro. | Gene therapy | 2002 | name in title: HSV1716 |
| PMID 11020355 | Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model. | Molecular therapy : the journal of the American Society of Gene Therapy | 2000 | name in abstract: HSV1716 |
| PMID 10389942 | Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 1999 | name in abstract: HSV1716 |
| PMID 10585055 | Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system. | The Annals of thoracic surgery | 1999 | name in abstract: HSV1716 |
| PMID 10609661 | Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. | Human gene therapy | 1999 | name in title: HSV1716 |
| PMID 9012475 | Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. | Cancer research | 1997 | name in abstract: HSV1716 |
| PMID 9182825 | Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. | The Journal of investigative dermatology | 1997 | name in abstract: HSV1716 |
| PMID 9400985 | Herpes simplex virus 1716, an ICP 34.5 null mutant, is unable to replicate in CV-1 cells due to a translational block that can be overcome by coinfection with SV40. | The Journal of general virology | 1997 | name in abstract: HSV1716 |
| PMID 8806577 | Herpes simplex 1716--an ICP 34.5 mutant--is severely replication restricted in human skin xenografts in vivo. | Virology | 1996 | name in abstract: HSV1716 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R33NS128191 | Development of murine glioblastoma model for oncolytic HSV therapy | LSU HEALTH SCIENCES CENTER | KAUR, BALVEEN | 2026–2026 | name in abstract: HSV1716 |
| R61NS128191 | Development of murine glioblastoma model for oncolytic HSV therapy | AUGUSTA UNIVERSITY | KAUR, BALVEEN | 2024–2025 | name in abstract: HSV1716 |
| R21CA191544 | CendR peptide-mediated enhancement of systemic oncolytic herpes virotherapy | RESEARCH INST NATIONWIDE CHILDREN'S HOSP | CRIPE, TIMOTHY P | 2015–2016 | name in abstract: HSV1716 |
| R01FD003717 | Phase I Study of HSV1716 in Pediatric Non-CNS Solid Tumors,IND 13196 12/04/2006 | RESEARCH INST NATIONWIDE CHILDREN'S HOSP | CRIPE, TIMOTHY P | 2010–2014 | name in title: HSV1716 |
Notes
First engineered oncolytic HSV given to humans (glioma, Edinburgh/Glasgow, published 2000). Later sponsors Crusade Laboratories then Virttu Biologics; Virttu acquired by Sorrento Therapeutics 2017. No recent trials found; treated as discontinued.
How to cite
HSV1716 (AXP000073.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000073.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.